

HLA-DRβ3 (h): 293T Lysate: sc-110914

BACKGROUND

Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4⁺ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in MHC class IIα/β dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM and HLA-DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane anchored heavy chain and a light chain (β-2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.

REFERENCES

- Horejsí, V., Nemec, M., Angelisová, P., Kristofová, H., Gorga, J.C. and Hilgert, I. 1986. Characterization of seven new monoclonal antibodies against human DR, DR/DP and DQ1/DQ3 antigens. *Tissue Antigens* 28: 288-297.
- Horejsí, V., Hilgert, I., Kristofová, H., Bazil, V., Bukovský, A. and Kulhánková, J. 1986. Monoclonal antibodies against human leucocyte antigens. I. Anti-bodies against β-2-microglobulin, immunoglobulin κ light chains, HLA-DR-like antigens, T8 antigen, T1 antigen, a monocyte antigen, and a pan-leucocyte antigen. *Folia Biol.* 32: 12-25.
- Kropshofer, H., Vogt, A.B., Thery, C., Armandola, E.A., Li, B.C., Moldenhauer, G., Amigorena, S. and Hammerling, G.J. 1998. A role for HLA-DO as a cochaperone of HLA-DM in peptide loading of MHC class II molecules. *EMBO J.* 17: 2971-2981.
- Siegmund, T., Donner, H., Braun, J., Usadel, K.H. and Badenhop, K. 1999. HLA-DMA and HLA-DMB alleles in German patients with type 1 diabetes mellitus. *Tissue Antigens* 54: 291-294.
- Arndt, S.O., Vogt, A.B., Markovic-Plese, S., Martin, R., Moldenhauer, G., Wolpl, A., Sun, Y., Schadendorf, D., Hammerling, G.J. and Kropshofer, H. 2000. Functional HLA-DM on the surface of B cells and immature dendritic cells. *EMBO J.* 19: 1241-1251.
- Brunet, A., Samaan, A., Deshaies, F., Kindt, T.J. and Thibodeau, J. 2000. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DOβ. *J. Biol. Chem.* 275: 37062-37071.
- Doebele, C.R., Busch, R., Scott, M.H., Pashine, A. and Mellins, D.E. 2000. Determination of the HLA-DM interaction site on HLA-DR molecules. *Immunity* 13: 517-527.
- Louis-Pence, P., Kerlan-Candon, S., Morel, J., Combe, B., Clot, J., Pinet, V. and Eliaou, J.F. 2000. The downregulation of HLA-DM gene expression in rheumatoid arthritis is not related to their promoter polymorphism. *J. Immunol.* 16: 4861-4869.

CHROMOSOMAL LOCATION

Genetic locus: HLA-DRB3 (human) mapping to 6p21.32.

PRODUCT

HLA-DRβ3 (h): 293T Lysate represents a lysate of human HLA-DRβ3 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

HLA-DRβ3 (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive HLA-DRβ3 antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

HLA-DR/DP (MEM-136): sc-51618 is recommended as a positive control antibody for Western Blot analysis of enhanced human HLA-DRβ3 expression in HLA-DRβ3 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



HLA-DR/DP (MEM-136): sc-51618. Western blot analysis of HLA-DRβ3 expression in non-transfected: sc-117752 (A) and human HLA-DRβ3 transfected: sc-110914 (B) 293T whole cell lysates.



HLA-DR (Bra30): sc-33717. Western blot analysis of HLA-DRβ3 expression in non-transfected: sc-117752 (A) and human HLA-DRβ3 transfected: sc-110914 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.